Lysogene
Latest round
- Series A
Last raised
- May 2014
Total raised
- $23M
Investors
- 3
About Lysogene
A.A. specializes in gene therapy research, particularly targeting rare neurological disorders. The company has undergone pivotal developments in its strategic direction. Karen Aiach, the founder and current CEO, has previously operated in other ventures within the life sciences sector.8 per share, marking a significant financial milestone for the firm.A. focuses on developing gene therapies to treat severe neurodegenerative diseases, leveraging advanced genetic technologies.Lysogene plans to enhance its product offerings with new gene therapy candidates aimed at treating rare neurological disorders, with specific candidates expected to launch in the coming years. The company is targeting expansion into European and North American markets by 2025.
Who invested in Lysogene
3 investors across 1 round
See all investors in Lysogene
Sign up free to see every VC on the cap table, the rounds they joined, and how much each round raised.
Funding rounds
Series A
May 21, 2014
Amount
$23M
Investors
Questions about Lysogene
Who invested in Lysogene?
Lysogene has 3 investors on record across 1 venture round. Sign up free to see every VC on the cap table and the rounds they joined.
How much funding has Lysogene raised?
Lysogene has raised 1 venture round. Sign up free to see how much each round raised and the total.
When did Lysogene last raise money?
Lysogene's most recent round on record is a Series A, in May 2014.
What does Lysogene do?
Lysogene is a biotechnology company.
Where is Lysogene headquartered?
Lysogene is headquartered in France.
Which VCs invest in companies like Lysogene?
Among active investors with capital left to deploy, Index Ventures, Forbion, European Investment Bank and Highland Europe back biotechnology companies at Lysogene's stage. Their profiles are linked below.
VCs backing biotechnology startups at Series A
Raising like Lysogene? Find the right VCs.
Capital Atlas matches your startup to active investors by stage, sector and region.